文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症成人尿素轨迹与蛋白质剂量之间的关联:EFFORT Protein 试验的二次探索性分析(RE-EFFORT)

Association between urea trajectory and protein dose in critically ill adults: a secondary exploratory analysis of the effort protein trial (RE-EFFORT).
PubMed 文献 · Crit Care · 2024-01-16
一句话结论EFFORT Protein 再分析提示高蛋白组30天死亡风险升高可能由尿素循环活性增加介导,启动和继续输注蛋白质时应考虑血清尿素。

本研究为 EFFORT Protein 随机对照试验的二次探索性分析,纳入1301例中的1277例机械通气重症患者,采用贝叶斯联合模型评估尿素与30天生存的关联及高蛋白剂量的治疗效应。高蛋白组第6天尿素中位数较高蛋白对照组高2.1 mmol/L(95%CI 1.1-3.2),第12天升至3.0 mmol/L(95%CI 1.3-4.7);调整年龄、疾病严重程度、肾脏替代治疗和AKI后,尿素升高两倍与30天死亡风险增加相关(HR 1.34,95%可信区间1.21-1.48),该关联在30天随访期间及调整器官衰竭演变后持续存在。作者认为EFFORT Protein中高蛋白组死亡风险增加可能由尿素循环活性增加介导,血清尿素是其生物学标志,启动和继续蛋白质输注时应考虑血清尿素。

要点

  • 高蛋白组第6天尿素中位数较对照组高2.1 mmol/L(95%CI 1.1-3.2),第12天高3.0 mmol/L(95%CI 1.3-4.7)。
  • 调整年龄、疾病严重程度、肾脏替代治疗和AKI后,尿素升高两倍与30天死亡风险增加相关(HR 1.34,95%可信区间1.21-1.48)。
  • 该关联在30天随访期间持续存在,并在调整器官衰竭随时间演变的模型中仍存在。
  • 作者认为高蛋白组死亡风险增加可能由尿素循环活性增加介导,血清尿素是其生物学标志。
  • 作者建议启动和继续重症患者蛋白质输注时应考虑血清尿素。

适用人群与场景

  • EFFORT Protein 试验纳入的机械通气重症成人,共1301例,本分析纳入1277例。

研究设计与关键结果

  • 研究类型:EFFORT Protein 随机对照试验的二次探索性分析(RE-EFFORT),采用贝叶斯联合模型。
  • 样本量:EFFORT Protein 纳入1301例,本分析纳入1277例;随机化后30天死亡344例。
  • 高蛋白组第6天尿素中位数较对照组高2.1 mmol/L(95%CI 1.1-3.2),第12天高3.0 mmol/L(95%CI 1.3-4.7)。
  • 调整年龄、疾病严重程度、肾脏替代治疗和AKI后,尿素升高两倍与30天死亡风险增加相关(HR 1.34,95%可信区间1.21-1.48)。
  • 该关联在30天随访期间持续存在,并在调整器官衰竭随时间演变的模型中仍存在。

证据类型、等级与局限

  • 证据类型:随机对照试验的二次探索性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,EFFORT Protein 中高蛋白组死亡风险增加可能由尿素循环活性增加介导,血清尿素是其生物学标志。
  • 作者建议启动和继续重症患者蛋白质输注时应考虑血清尿素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Delivering higher doses of protein to mechanically ventilated critically ill patients did not improve patient outcomes and may have caused harm. Longitudinal urea measurements could provide additional information about the treatment effect of higher protein doses. We hypothesised that higher urea values over time could explain the potential harmful treatment effects of higher doses of protein.

METHODS: We conducted a reanalysis of a randomised controlled trial of higher protein doses in critical illness (EFFORT Protein). We applied Bayesian joint models to estimate the strength of association of urea with 30-day survival and understand the treatment effect of higher protein doses.

RESULTS: Of the 1301 patients included in EFFORT Protein, 1277 were included in this analysis. There were 344 deaths at 30 days post-randomisation. By day 6, median urea was 2.1 mmol/L higher in the high protein group (95% CI 1.1-3.2), increasing to 3.0 mmol/L (95% CI 1.3-4.7) by day 12. A twofold rise in urea was associated with an increased risk of death at 30 days (hazard ratio 1.34, 95% credible interval 1.21-1.48), following adjustment of baseline characteristics including age, illness severity, renal replacement therapy, and presence of AKI. This association persisted over the duration of 30-day follow-up and in models adjusting for evolution of organ failure over time.

CONCLUSIONS: The increased risk of death in patients randomised to a higher protein dose in the EFFORT Protein trial was estimated to be mediated by increased urea cycle activity, of which serum urea is a biological signature. Serum urea should be taken into consideration when initiating and continuing protein delivery in critically ill patients.

CLINICALTRIALS: gov Identifier: NCT03160547 (2017-05-17).

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Haines RW, Prowle JR, Day A, et al. Association between urea trajectory and protein dose in critically ill adults: a secondary exploratory analysis of the effort protein trial (RE-EFFORT). Crit Care. 2024. PMID: 38229072. doi:10.1186/s13054-024-04799-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。